Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever.

The article identifies three healthcare-related dividend stocks offering attractive yields for institutional investors, each with distinct risk profiles. Kenvue, a consumer staples spin-off from Johnson & Johnson, currently yields 5.5% despite recent stock pressure from a Tylenol controversy and lowered guidance, but is presented as a resilient long-term holding due to its strong brand portfolio. Medtronic, yielding around 3% and nearing Dividend King status, is strategically spinning off its diabetes division to enhance profitability and growth, aiming to improve investor sentiment. Pfizer, offering the highest yield at nearly 7%, is considered a high-risk, high-reward turnaround play, facing potential dividend cuts due to a high payout ratio, patent expirations, and the Metsera acquisition, yet demonstrating a commitment to long-term viability through strategic M&A.

Analysis

Kenvue, a consumer staples spin-off from Johnson & Johnson, currently offers a 5.5% dividend yield, significantly elevated due to recent stock pressure. This pressure stems from a Tylenol controversy and a lowered full-year guidance for 2025, reflecting short-term business headwinds. However, its portfolio of iconic brands suggests underlying resilience and customer loyalty, positioning it as a potentially stable long-term holding despite current negativity.

Medtronic, a medical device company, is approaching "Dividend King" status with 48 consecutive years of dividend increases, signaling strong commitment to shareholder returns. Its strategic spinoff of the diabetes division aims to enhance profitability and growth, with the move expected to be instantly accretive to earnings. Despite a historically elevated 3% yield, investor sentiment remains cautious, awaiting concrete results from this business overhaul.

Pfizer presents a high-risk, high-reward scenario with a nearly 7% dividend yield, but a payout ratio close to 100% and upcoming patent expirations pose significant dividend cut risks. The Metsera acquisition, while potentially leading to a dividend haircut, is a strategic move to bolster its drug pipeline and demonstrates the company's commitment to long-term viability. Investors should view Pfizer as a turnaround play, acknowledging its resilience as a major pharmaceutical entity.

Key Decisions for Investors

• For Kenvue, assess the long-term value proposition of its strong brand portfolio against current negative sentiment and lowered guidance, considering it for a high-yield, consumer staples allocation.
• Monitor Medtronic's execution of its diabetes division spinoff and new product launches, as successful implementation could re-rate the stock and solidify its dividend growth trajectory.
• Evaluate Pfizer's high yield in the context of its elevated dividend payout risk and patent cliff challenges, weighing the potential for a dividend reset against the long-term strategic benefits of its M&A activities.